curasan AG develops, produces, and markets biomaterials and medical devices for bone and tissue regeneration worldwide. More Details
Mediocre balance sheet and overvalued.
Share Price & News
How has curasan's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: CURK's share price has been volatile over the past 3 months.
7 Day Return
1 Year Return
Return vs Industry: CURK underperformed the German Biotechs industry which returned -5.4% over the past year.
Return vs Market: CURK underperformed the German Market which returned 0.1% over the past year.
Price Volatility Vs. Market
How volatile is curasan's share price compared to the market and industry in the last 5 years?
Simply Wall St News
2 months ago | Simply Wall StLoss-Making curasan AG (ETR:CURK) Expected To Breakeven
7 months ago | Simply Wall StWhat Kind Of Shareholder Owns Most curasan AG (ETR:CURK) Stock?
9 months ago | Simply Wall StThe curasan (ETR:CURK) Share Price Is Down 74% So Some Shareholders Are Rather Upset
Is curasan undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate CURK's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate CURK's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: CURK is unprofitable, so we can't compare its PE Ratio to the XE Biotechs industry average.
PE vs Market: CURK is unprofitable, so we can't compare its PE Ratio to the German market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate CURK's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: CURK is good value based on its PB Ratio (0.2x) compared to the DE Biotechs industry average (3.9x).
How is curasan forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
Forecasted Pharmaceuticals & Biotech industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as curasan has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
- Take a look at our analysis of CURK’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
- curasan competitive advantages and company strategy can generally be found in its financial reports archived here.
- Explore growth companies in the Pharmaceuticals & Biotech industry.
How has curasan performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: CURK is currently unprofitable.
Growing Profit Margin: CURK is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: CURK is unprofitable, and losses have increased over the past 5 years at a rate of 39.4% per year.
Accelerating Growth: Unable to compare CURK's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: CURK is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (15.2%).
Return on Equity
High ROE: CURK has a negative Return on Equity (-75.33%), as it is currently unprofitable.
How is curasan's financial position?
Financial Position Analysis
Short Term Liabilities: CURK's short term assets (€5.1M) exceed its short term liabilities (€2.4M).
Long Term Liabilities: CURK's short term assets (€5.1M) exceed its long term liabilities (€2.0M).
Debt to Equity History and Analysis
Debt Level: CURK's debt to equity ratio (30.1%) is considered satisfactory.
Reducing Debt: CURK's debt to equity ratio has increased from 0.7% to 30.1% over the past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: Insufficient data to determine if CURK has enough cash runway based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if CURK has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.
What is curasan current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate CURK's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate CURK's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if CURK's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if CURK's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: CURK is not paying a notable dividend for the German market.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of CURK's dividend in 3 years as they are not forecast to pay a notable one for the German market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Dr. Alexander Baratta serves as Chief Executive Officer at curasan AG since March 16, 2020 and serves as its Chairman of Management Board since March 16, 2020.
|Chairman of Management Board & CEO||0.58yr||no data||no data|
|Technical Director||no data||no data||no data|
|Head of Corporate Communications & Investor Relations||no data||no data||no data|
|Head of Marketing & Sales||5.5yrs||no data||no data|
|President of USA||4.42yrs||no data||no data|
Experienced Management: CURK's management team is considered experienced (4.4 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
curasan AG's company bio, employee growth, exchange listings and data sources
- Name: curasan AG
- Ticker: CURK
- Exchange: XTRA
- Founded: 1988
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: €1.179m
- Shares outstanding: 9.07m
- Website: https://www.curasan.de
Number of Employees
- curasan AG
- Lindigstrasse 4
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|CURK||DB (Deutsche Boerse AG)||Yes||Bearer Shares||DE||EUR||Jul 2000|
|CURK||XTRA (XETRA Trading Platform)||Yes||Bearer Shares||DE||EUR||Jul 2000|
curasan AG develops, produces, and markets biomaterials and medical devices for bone and tissue regeneration worldwide. The company specializes in offering biomimetic bone regeneration materials, which are ...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/10/24 20:44|
|End of Day Share Price||2020/09/29 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.